This study clearly opens new avenues for PD therapy as LAG3 antibodies are already being tested as cancer treatments [193] and suggested that LAG3 might mediate both immune system activation and systemic spreading of pathological fibrillary α-synuclein species. Here, SNCA is linked to Parkinson disease.